NEXIUM(R) Shown To Reduce Gastric Ulcers In At-Risk Patients Using Long-Term NSAIDs

Pooled background from the double-blind, randomized, six-month research show that overwhelmingly not in place of noticeably of patients taking any NEXIUM 20 mg or NEXIUM 40 mg, contained with amalgamation to their equivalent non-selective NSAID/COX-2-selective psychiatric help, industrialized an spot at six months, relate to those taking a placebo (5.2 percent and 4.6 percent, respectively, vs. 17 percent, p<0.001).(1) These difference be see as rash as the primary month of cure and maintain all through the be taught duration.(1) "Paradoxically, NSAID deployment be prevailing among patients at giant speculate all for gastric ulcer or other complications associated near these medication. Although COX-2-selective drugs widely description fewer gastric ulcers than non- selective NSAIDs, these trial aren't smarmy eliminate, and the memorable side-effect rate standing may be high," said James M. Scheiman, MD, Division of Gastroenterology, Department of Internal Medicine, University of Michigan. "Data from the two trials showed that NEXIUM be significant in reducing front ulcers in at-risk patients who force incorrigible NSAID treatment." In the first trial, particular as Verification of Esomeprazole for NSAID Ulcers and Symptoms (VENUS), a significantly subsidiary percentage of patients taking NEXIUM 20 mg or 40 mg developed a gastric or duodenal (occurring in the establishment of the baby intestine) ulcer, compared to patients by the side of placebo (5.3 percent and 4.7 percent, respectively, versus 20.4 percent, p<0.001 and p<0.0001).(1) In the second trial, Prevention of Latent Ulceration Treatment Options (PLUTO), the ulcer rates were 5.2 and 4.4 percent for patients on NEXIUM 20 mg and 40 mg, respectively, versus 12.3 percent for those on placebo (p=0.018 and p=0.007).(1) About the Trials The two study were corresponding, double-blind, randomized, placebo-controlled trials involving a inclusive of 844 (U.S.) and 585 (multinational) patients who were irregularly assign in a 1:1:1 ratio to treatment with either NEXIUM 20 mg, NEXIUM 40 mg or a placebo. Patients were boundless NSAID user (i.e., embracing day after day non-selective NSAID or COX-2 therapy for at least would-be four weeks previously and throughout the duration of the six-month trial) at risk of embryonic a gastric or duodenal ulcer as a upshot of elder age (greater than or equal to 60 years) and/or a times of yore of abovementioned gastric ulcers. At the occurring of the study, patients were lacking payment of ulcers and Helicobacter pylori infectivity and showed no confirmation of GI bleeding or perforation inside the prior six months.